• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search
Home » About Rebiotix

About Rebiotix

Rebiotix is on the forefront of an exciting potential medical breakthrough

Harnessing the Power of the Human Microbiome

Rebiotix Inc., a Ferring Company, is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome.

The company is on the forefront of an exciting potential medical breakthrough with our MRT™ drug platform.  The MRT drug platform is leveraged to develop formulations consisting of live microbes, which are evaluated through our clinical program for the formulation’s ability to address challenging diseases.

Rebiotix looks to deliver on the promise of restoring the gut microbiota via standardized and stabilized investigational drugs that have been developed and tested under the auspices of a regulatory authority.

Video play time is 1:00 minute.

Key Milestones in Harnessing the Power of the Human Microbiome

  • Rebiotix was founded

    2011

  • Pre-Investigational New Drug (IND) meeting with FDA for RBX2660

    2012

  • FDA IND granted

    Fast Track designation granted

    PUNCH CD Phase 2 trial enrolled for RBX2660 to treat recurrent Clostridioides difficile

    2013

  • FDA Orphan Drug designation granted

    Results of PUNCH CD announced

    PUNCH CD 2 (phase 2b) trial initiated

    Development of oral formulation, RBX7455, started

    2014

  • PUNCH CD 2 enrollment for RBX2660 completed

    FDA Breakthrough Therapy Status granted for RBX2660

    Oral formulation Drug Master File (DMF) filed with FDA

    2015

  • PUNCH CD 2 Randomized Double Blind Placebo Control Study results confirming Phase 2 data

    RBX7455 Non-Frozen Capsule feasibility study initiated

    2016

  • Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridioides difficile

    Phase 3 PUNCH CD3 initiated Q3 2017

    2017

  • Ferring acquires Rebiotix in April

    2018

  • Phase 3 Open Label PUNCH CD3-OLS Initiated Q2 2019

    2019

  • Phase 3 PUNCH CD3 Enrollment Completed

    Phase 3 PUNCH CD3 Positive Topline Results Announced

    2020

  • Phase 3 PUNCH CD3 Data presented at DDW 2021

    Phase 3 Open Label PUNCH CD3-OLS Interim Results presented at DDW 2021

    2021


Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us